Where does David Bonita work?

David Bonita is General Partner at OrbiMed and Board director at Mirador Therapeutics and Board director at Treeline Biosciences and Board director at Adela.

What check size does David Bonita write?

David Bonita typically writes checks of $1M – $75M.

What boards does David Bonita sit on?

David Bonita holds tracked board seats at Acutus Medical, Adela, Clementia Pharmaceuticals, Ikena Oncology, Inc., Imara, Prelude Therapeutics, SI-BONE, Thrombolex, Treeline Biosciences, Tricida.

What companies has David Bonita invested in?

Investments tracked here include Ambit Biosciences, Clementia Pharmaceuticals, Congruence Therapeutics, Imara, Loxo Oncology, Magenta Medical, Rampart Bioscience, Repare Therapeutics, SI-BONE, Sublimity Therapeutics, Third Harmonic Bio, Tricida, and 1 more.

Where did David Bonita go to school?

David Bonita studied at Columbia Business School (MBA); Columbia University Vagelos College of Physicians and Surgeons (MD); Harvard University (BA, Biology).

David Bonita

Investor

General Partner at OrbiMed · Board director at Mirador Therapeutics · Board director at Treeline Biosciences · Board director at Adela

New York, New York

Writes $1M – $75M checks · typically $4M

Find your path to David

738 people in our graph can introduce you to David.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Deborah Palestrant to introduce you to David

You →Deborah · together at Columbia University Vagelos College of Physicians and Surgeons (1999–2000) →David

Ask Jamie Chen to introduce you to David

You →Jamie · 2 people · together at Columbia University Vagelos College of Physicians and Surgeons →David

Ask Sam Okafor to introduce you to David

You →Sam · 6 people · together at OrbiMed →David

Your email: the people you already email who know David
2nd- and 3rd-degree connections: people you know who worked, studied or invested with David
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.

Invests in

AI & Machine LearningBiotechHealthtechMedical Devices

Board director at Mirador Therapeutics

Intro paths

→

In turn, David can intro founders to Mirador Therapeutics's investors below.

Mirador Therapeutics's investors · 7

Aquiline Technology GrowthNew York ARCH Venture PartnersChicago · $50K – $250M checks · since 2024 InvusNew York · since 2026 OrbiMedNew York · $1M – $75M checks · since 2024 Point72Stamford · since 2026 Sanofi VenturesCambridge · $5M checks · since 2024 Venrock Healthcare Capital PartnersNew York · since 2026

Co-founders at Mirador Therapeutics

Mark C. McKennaExecutive Officer, Director

Board director at Treeline Biosciences

Intro paths

→

In turn, David can intro founders to Treeline Biosciences's investors below.

Treeline Biosciences's investors · 9

Aisling CapitalNew York · since 2025 ARC VENTURESNew York ARCH Venture PartnersChicago · $50K – $250M checks · since 2025 Casdin CapitalNew York · since 2025 Fidelity InvestmentsBoston · since 2025 GV (Google Ventures)Mountain View · $250K – $50M checks · since 2025 OrbiMedNew York · $1M – $75M checks · since 2025 Rock Springs CapitalBaltimore · since 2025 T. Rowe PriceBaltimore · since 2025

Co-founders at Treeline Biosciences

Joshua H. BilenkerExecutive Officer, Director, Promoter

Jeffrey EngelmanExecutive Officer, Director, Promoter

Josh BilenkerFounder

Board director at Adela

Intro paths

→

In turn, David can intro founders to Adela's investors below.

Adela's investors · 5

Decheng CapitalMenlo Park Deerfield Management CompanyNew York · since 2025 F-Prime CapitalCambridge · $3M – $10M checks · since 2021 Menlo VenturesSan Francisco · $1M – $20M checks OrbiMedNew York · $1M – $75M checks · since 2026

Co-founders at Adela

Daniel Diniz De CarvalhoExecutive Officer, Promoter

Scott BratmanExecutive Officer, Director

Anne-Renee HartmanFounder

Experience

OrbiMedGeneral Partnercurrent2020 — present
OrbiMedPrivate Equity Partner2013 — 2020
OrbiMedPrivate Equity Principal2007 — 2013
OrbiMedSenior Associate2004 — 2007
Morgan StanleyFinancial Analyst1998 — 1999
UBS Investment BankFinancial Analyst1997 — 1998

Skills & more

Venture CapitalPrivate EquityFinancial Modeling2Due DiligenceValuation

From David's professional profile.

Deals · 10

ThrombolexBoard seat

via OrbiMed · filed Mar 2026 · $51.1M raise

Treeline BiosciencesBoard seat

via OrbiMed · filed Sep 2025 · $250M raise

Ikena Oncology, Inc.Board seat

via OrbiMed · filed Jul 2025 · $75M raise

Acutus MedicalBoard seat

via OrbiMed · filed Jul 2022 · $4.2M raise

ImaraBoard seat

via OrbiMed · filed Mar 2019 · $63M raise

TricidaBoard seat

via OrbiMed · filed Jul 2016 · $55.5M raise

Prelude TherapeuticsBoard seat

via OrbiMed · filed Jul 2016 · $5M raise

SI-BONEBoard seat

via OrbiMed · filed Jun 2016 · $21M raise

ViewrayBoard seat

via OrbiMed · filed Aug 2015

Clementia PharmaceuticalsBoard seat

via OrbiMed · filed Jul 2015 · $60M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Adela

Investor

Ambit BiosciencesCongruence Therapeutics Loxo Oncology Magenta Medical Rampart BioscienceRepare TherapeuticsSublimity TherapeuticsThird Harmonic BioWindward Bio

Sources: SEC Form D filings · curated public sources.

Leave your own feedback

Colleagues at OrbiMed

Alexander M. Cooper

Investor at OrbiMed

Anat Nursella

Venture Partner at OrbiMed

Andrew P. Kanarek, CFA, CIPM

Venture Partner at OrbiMed

Network5

Alexandria Huynh

Analyst at OrbiMed

Anat Nursella

Venture Partner at OrbiMed

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Bonita?: David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.
Where does David Bonita work?: David Bonita is General Partner at OrbiMed and Board director at Mirador Therapeutics and Board director at Treeline Biosciences and Board director at Adela.
What does David Bonita invest in?: David Bonita invests in AI & Machine Learning, Biotech, Healthtech, Medical Devices.
What check size does David Bonita write?: David Bonita typically writes checks of $1M – $75M.
What boards does David Bonita sit on?: David Bonita holds tracked board seats at Acutus Medical, Adela, Clementia Pharmaceuticals, Ikena Oncology, Inc., Imara, Prelude Therapeutics, SI-BONE, Thrombolex, Treeline Biosciences, Tricida.
What companies has David Bonita invested in?: Investments tracked here include Ambit Biosciences, Clementia Pharmaceuticals, Congruence Therapeutics, Imara, Loxo Oncology, Magenta Medical, Rampart Bioscience, Repare Therapeutics, SI-BONE, Sublimity Therapeutics, Third Harmonic Bio, Tricida, and 1 more.
Where did David Bonita go to school?: David Bonita studied at Columbia Business School (MBA); Columbia University Vagelos College of Physicians and Surgeons (MD); Harvard University (BA, Biology).